Giuseppe Viale

1. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
   2020/01/13 by Kimberly H. Allison, M. Elizabeth H. Hammond, Mitch Dowsett +17 · 10 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Breast Lesions and Carcinomas #Estrogen and related hormone effects
2. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
   2016/07/01 by Carsten Denkert, Stephan Wienert, Audrey Poterie +57 · 4 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Cells and Metastasis #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers
3. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
   2015/09/04 by Fausto Petrelli, Giuseppe Viale, G. Viale +4 · 2 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Breast Lesions and Carcinomas #Cancer Genomics and Diagnostics
4. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
   2022/02/16 by L. Gianni, Luca Gianni, C.S. Huang +35 · 2 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Cancer Immunotherapy and Biomarkers #HER2/EGFR in Cancer Research
5. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
   2018/05/30 by Antonio C. Wolff, M. Elizabeth Hammond, M. Elizabeth Hale Hammond +18 · 1 citation
   Medicine · #Chronic Lymphocytic Leukemia Research #HER2/EGFR in Cancer Research #Monoclonal and Polyclonal Antibodies Research
6. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
   2017/10/12 by Maria Vittoria Dieci, Nina Radosevic-Robin, Nina Radosevic‐Robin +33 · 1 citation
   Immunology and Microbiology · Medicine · #Cancer Cells and Metastasis #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses